Novel compounds
2 Assignments
0 Petitions
Accused Products
Abstract
Novel substituted 1,5,7-trisubstituted-3,4-dihydro-pyrimido[4,5-d]pyrimidin-2-(1H)-one compounds and compositions, and their use in therapy as CSBP/RK/p38 kinase inhibitors.
70 Citations
133 Claims
-
1. A compound of the formula:
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 81, 82, 83, 86, 95, 96, 98, 99, 100)
-
2. The compound according to claim 1 which is Formula (I), or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.
-
3. The compound according to claim 1 which is Formula (Ia), or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.
-
4. The compound according to claim 1 wherein R1 is C(Z)N(R10′
- )(CR10R20)vRb or N(R10′
)C(Z)(CR10R20)vRb.
- )(CR10R20)vRb or N(R10′
-
5. The compound according to claim 4 wherein R1 is C(Z)N(R10′
- )(CR10R20)vRb.
-
6. The compound according to claim 1 wherein Rb is selected from an optionally substituted alkyl, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted aryl C1-10 alkyl, or an optionally substituted C3-7 cycloalkyl C1-10 alkyl.
-
7. The compound according to claim 6 wherein Rb is optionally substituted alkyl, optionally substituted heteroaryl, or an optionally substituted aryl.
-
8. The compound according to claim 7 wherein Rb is propyl, isopropyl, thiazolyl, phenyl, or 4-F phenyl.
-
9. The compound according to claim 6 wherein Rb is an optionally substituted aryl or aryl C1-10alkyl moiety, and the aryl ring substituted independently at each occurrence one or more times by halogen, alkyl, cyano, OR8, SR5, S(O)2R5, C(O)Rj, C(O)ORj, -Z′
- -(CR10R20)s-Z′
, halosubstituted C1-10 alkyl, or an optionally substituted aryl; and
whereinR8 is independently selected at each occurrence from hydrogen, C1-4 alkyl, halo-substituted C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C3-7 cycloalkyl, C3-7 cycloalkyl C1-4 alkyl, C5-7 cycloalkenyl, C5-7cycloalkenyl C1-4 alkyl, aryl, arylC1-4 alkyl, heteroaryl, heteroarylC1-4 alkyl, heterocyclyl, or a heterocyclylC1-4 alkyl moiety, and wherein these moieties, excluding hydrogen, may be optionally substituted;
Rj is independently selected at each occurrence from hydrogen, C1-4alkyl, aryl, aryl C1-4alkyl, heteroaryl, heteroaryl C1-4alkyl, heterocyclic, or a heterocyclic C1-14alkyl moiety, and wherein these moieties, excluding hydrogen, may be optionally substituted;
Z′
is independently selected at each occurrence from oxygen, or sulfur; and
s is an integer having a value of 1, 2, or 3, independently selected at each occurrence.
- -(CR10R20)s-Z′
-
10. The compound according to claim 1 wherein Rb is phenyl, napthylene, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,4-diflurophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3-chloro-4-fluorophenyl, 2-methyl phenyl, 3-methylphenyl, 4-methylphenyl, 6-methyl phenyl, 2-methyl phenyl, 3-amino phenyl, 3,4-dimethyl phenyl, 4-methyl-3-fluorophenyl, 4-trifluorophenyl, 4-ethoxyphenyl, 4-methoxyphenyl, 3-cyanophenyl, 4-cyanophenyl, 4-thiomethylphenyl, 4-acetylphenyl, 4-dimethylaminophenyl, benzyl, phenethyl, phenylpropyl, 2,3-difluoro-benzyl, 3,5-difluoro-benzyl, biphenyl, 4′
- -fluorobiphenyl, 4-sulfonamindo-2-methylphenyl, 3-phenyloxyphenyl, 4-phenyloxyphenyl, 4-(1-piperidinylsulfonyl)-phenyl, or 3-(aminocarbonyl)phenyl.
-
11. The compound according to claim 6 wherein Rb is a C1-10alkyl, or a C1-10alkyl substituted one or more times, independently by halogen, cyano, alkoxy, thiol, or hydroxy.
-
12. The compound according to claim 11 wherein Rb is methyl, ethyl, propyl, isopropyl, t-butyl, butyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, heptyl, 2-methylpropyl, 2,2,2-trifluroethyl, 2-fluoroethyl, cyanomethyl, cyanoethyl, 2-methoxy-ethyl, 2-hydroxy propyl, serinol, or ethylthioethyl.
-
13. The compound according to claim 6 wherein Rb is an optionally substituted heteroaryl, heteroaryl C1-10alkyl, heterocyclic or heterocyclic C1-10alkyl.
-
14. The compound according to claim 13 wherein Rb is the moiety is a 1,3-thiazol-2-yl, 5-methyl-1,3-thiazol-2-yl, isoquinoline, 3-thiophene, indol-5yl, pyridin-3-yl, pyridine-4-yl, indazolyl, benzothiazolyl, 2-methyl-1,3-benzothiazol-5-yl, pyrazol-3-yl, 4-morpholino, 2-furanyl, 2-furanylmethyl, 2-thienyl, 2-thienylmethyl, tetrahydro-2H-pyran-4yl, tetrahydro-2H-pyran-4yl methyl, tetrahydro-2-furanyl, or tetrahydro-2-furanylmethyl, 2,3-dihydro-1,4-benzodioxin-6-yl, 1H-imidazol-4-yl or 1H-imidazol-4-yl-ethyl.
-
15. The compound according to claim 1 wherein Rb is an optionally substituted C3-7 cycloalkyl or C3-7 cycloalkyl C1-10alkyl.
-
16. The compound according to claim 15 wherein Rb is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, or cyclopentylmethyl.
-
17. The compound according to claim 6 wherein Rb is selected from methyl-1,3-benzothiazol-5-yl, 4′
- -fluoro-3-biphenyl, 4-fluoro-phenyl, 2-fluorophenyl, 4-chlorophenyl, 3,5-difluorophenyl, 3,4-difluorophenyl, 2,4-difluorophenyl, 4-fluorophenethyl, 3-chlorophenyl, 3-chloro-4-fluorophenyl, 4-acetylphenyl, 4-trifluorophenyl, 4-methyl-3-fluoro-phenyl, 4-thiomethylphenyl, 4-ethyloxyphenyl, 4-methoxyphenyl, 3-phenyloxyphenyl, 3-methylphenyl, 2-methylphenyl, 5-methyl-1,3-thiazol-2-yl, 3-pyridinyl, 4-pyridinyl, 4-cyanophenyl, 3-cyanophenyl, 4-(phenylcarbonyl)phenyl, 1H-indazol-6-yl, or 3-(aminosulfonyl)phenyl.
-
18. The compound according to claim 1 wherein the R1′
- is independently selected from halogen, C1-4 alkyl, or halo-substituted-C1-4 alkyl.
-
19. The compound according to claim 18 wherein the substituents are independently fluorine, methyl, or CF3.
-
20. The compound according to claim 18 wherein g is 1.
-
21. The compound according to claim 1 wherein X is S(O)mR2.
-
22. The compound according to claim 1 wherein X is (CH2)nNR4R14, or (CH2)nN(R2′
- )(R2″
).
- )(R2″
-
23. The compound according to claim 22 wherein X is (CH2)nNR4R14, and R4 and R14 are independently selected from hydrogen, optionally substituted C1-10 alkyl, optionally substituted aryl, optionally substituted aryl-C1-4 alkyl, optionally substituted heterocyclic, optionally substituted heterocylic C1-4 alkyl, optionally substituted heteroaryl or optionally substituted heteroaryl C1-4 alkyl.
-
24. The compound according to claim 23 wherein the C1-10 alkyl may be substituted one or more times, independently at each occurrence with NR4′
- R14′
;
halogen, hydroxy, alkoxy, C(O)NR4′
R14′
;
or NR4′
OC(O)C1-10alkyl.
- R14′
-
25. The compound according to claim 24 wherein R4′
- and R14′
;
are independently selected from hydrogen or a C1-4 alkyl.
- and R14′
-
26. The compound according to claim 25 wherein X is 3-(diethylamino)-propylamino.
-
27. The compound according to claim 22 wherein X is (CH2)nNR4R14 and one of R4 and R14 is an optionally substituted heteroaryl C1-4 alkyl, and the heteroaryl moiety is selected from thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, triazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, benzimidazolyl, and benzothiazolyl.
-
28. The compound according to claim 27 wherein the heteroaryl moiety is selected from pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, imidazolyl, benzoxazolyl, benzimidazolyl, and benzothiazolyl.
-
29. The compound according to claim 22 wherein X is (CH2)nNR4R14 and one of R4 and R14 is a heterocyclic C1-4 alkyl moiety selected from tetrahydropyrrole, tetrahydropyran, tetrahydrofuran, pyrrolinyl, pyrrolidinyl, imidazolinyl, imidazolidinyl, indolinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, diazepinyl, piperazinyl, and morpholino.
-
30. The compound according to claim 29 wherein the heterocyclic C1-4 alkyl moiety is selected from pyrrolinyl, pyrrolidinyl, piperidinyl, piperazinyl, and morpholino.
-
31. The compound according to claim 22 wherein X is (CH2)nNR4R14 and R4 and R14 together with the nitrogen cyclize to form an optionally substituted ring selected from pyrrolidine, piperidine, piperazine, and morpholine.
-
32. The compound according to claim 22 wherein the R4 and R14 cyclized ring is optionally substituted one or more times independently by an optionally substituted alkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclic, (CR10R20)nN(R10′
- )C(Z)OR7, or NR4′
R14′
.
- )C(Z)OR7, or NR4′
-
33. The compound according to claim 32 wherein the optional substituents are selected from phenyl, pyrrolidinyl, morpholino, piperazinyl, 4-methyl-1-piperazinyl, piperidinyl, 2-oxo-2,3-dihydro-1H-benzimidazol-1-yl, 5-chloro-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl, diphenylmethyl, methyl, ethyl, propyl, butyl, amino, methylamino, and dimethylamino.
-
34. The compound according to claim 1 wherein X is R2 and R2 is an optionally substituted heterocyclic or heterocyclic alkyl ring substituted one or more times independently at each occurrence by an optionally substituted heterocyclic, heterocyclic C1-10 alkyl, aryl, aryl C1-10 alkyl, C1-10 alkyl, (CR10R20)nNReRe′
- , or (CR10R20)nN(R10′
)C(Z)OR7.
- , or (CR10R20)nN(R10′
-
35. The compound according to claim 32 wherein R2 is selected from 1,4′
- -bipiperin-1-yl, 4-methyl-1,4′
-bipiperin-1-yl, 4-piperidinylamino, 4-amino-1-piperidinyl, 2,2,6,6-tetramethyl-4-piperidinyl)amino, 4-methyl-1-piperazinyl, (4-morpholinyl)-1-piperidinyl, (4-methyl-1-piperazinyl)-1-piperidinyl, 4-ethyl-1-piperazinyl, (2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinyl, 5-chloro-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinyl, 4-(1-pyrrolidinyl)-1-piperidinyl, 4-(diphenylmethyl)-1-piperazinyl, 4-methylhexahydro-1H-1,4-diazepin-1-yl, 4-propyl-1-piperazinyl, or 4-butyl-1-piperazinyl.
- -bipiperin-1-yl, 4-methyl-1,4′
-
36. The compound according to claim 35 wherein R2 is 1,4′
- -bipiperin-1-yl, 4-(1-pyrrolidinyl)-1-piperidinyl, and 4-methyl-1-piperazinyl.
-
37. The compound according to claim 1 wherein R2 is optionally substituted one or more times, independently at each occurrence, with C1-10 alkyl, halo-substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C3-7cycloalkylC1-10alkyl, C5-7cycloalkenyl, C5-7 cycloalkenyl C1-10 alkyl, halogen, —
- C(O), cyano, nitro, aryl, aryl C1-10 alkyl, heterocyclic, heterocyclic C1-10 alkyl, heteroaryl, heteroaryl C1-10 alkyl, (CR10R20)nOR6, (CR10R20)nSH, (CR10R20)nS(O)mR7, (CR10R20)nN(R10′
)S(O)2R7, (CR10R20)nNR4R14, (CR10R20)nCN, (CR10R20)nS(O)2NR4R14, (CR10R20)nC(Z)R6, (CR10R20)nOC(Z)R6, (CR10R20)nC(Z)OR6, (CR10R20)nC(Z)NR4R14, (CR10R20)nN(R10′
)C(Z)R6, (CR10R20)nN(R10′
)C(═
N(R10′
))NR4R14, (CR10R20)nC(═
NOR6)NR4R14, (CR10R20)nOC(Z)NR4R14, (CR10R20)nN(R10′
)C(Z)NR4R14, or (CR10R20)nN(R10′
)C(Z)OR7; and
whereinn is independently selected at each occurrence from 0 or an integer having a value of 1 to 10;
R6 is independently selected at each occurrence from hydrogen, C1-10alkyl, C3-7 cycloalkyl, heterocyclyl, heterocyclyl C1-10alkyl, aryl, arylC1-10 alkyl, heteroaryl or heteroarylC1-10 alkyl, wherein each of these moieties, excluding hydrogen are optionally substituted.
- C(O), cyano, nitro, aryl, aryl C1-10 alkyl, heterocyclic, heterocyclic C1-10 alkyl, heteroaryl, heteroaryl C1-10 alkyl, (CR10R20)nOR6, (CR10R20)nSH, (CR10R20)nS(O)mR7, (CR10R20)nN(R10′
-
38. The compound according to claim 36 wherein R2 is an optionally substituted alkyl.
-
39. The compound according to claim 38 wherein the C1-10alkyl is optionally substituted by (CR10R20)nC(Z)OR6, (CR10R20)nOR6, or (CR10R20)nNR4R14.
-
40. The compound according to claim 1 wherein R2 is (CR10R20)q′
- X1(CR10R20)qC(A1)(A2)(A3), or (CR10R20)q′
C(A1)(A2)(A3).
- X1(CR10R20)qC(A1)(A2)(A3), or (CR10R20)q′
-
41. The compound according to claim 40 wherein X1 is oxygen or N(R10′
- ).
-
42. The compound according to claim 41 wherein at least one of A1, A2 or A3 is substituted by (CR10R20)nOR6.
-
43. The compound according to claim 42 wherein q is 1 or 2, and q′
- is 0.
-
44. The compound according to claim 22 wherein X is (CH2)nN(R2′
- )(R2″
), and R2′
is an optionally substituted C1-10 alkyl, cycloalkyl, heterocyclic, heterocyclyl C1-10 alkyl, heteroarylalkyl.
- )(R2″
-
45. The compound according to claim 44 wherein the R2′
- moieties, excluding hydrogen, are optionally substituted 1 to 4 times, independently, at each occurrence, by C1-10 alkyl, halo-substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C3-7cycloalkylC1-10alkyl, C5-7cycloalkenyl, C5-7 cycloalkenylC1-10 alkyl, halogen, —
C(O), cyano, nitro, aryl, aryl C1-10 alkyl, aryl, aryl C1-10 alkyl, heterocyclic, heterocyclic C1-10 alkyl, heteroaryl, heteroaryl C1-10 alkyl, (CR10R20)nOR6, (CR10R20)nSH, (CR10R20)nS(O)mR7, (CR10R20)nN(R10′
)S(O)2R7, (CR10R20)nNReRe′
, (CR10R20)nNReRe′
C1-4alkylNReRe′
, (CR10R20)nCN, (CR10R20)nS(O)2NReRe′
, (CR10R20)nC(Z)R6, (CR10R20)nOC(Z)R6, (CR10R20)nC(Z)OR6, (CR10R20)nC(Z)NReRe′
, (CR10R20)nN(R10′
)C(Z)R6, (CR10R20)nN(R10′
)C(═
N(R10′
))NReRe′
, (CR10R20)nC(═
NOR6)NReRe′
, (CR10R20)nOC(Z)NReRe′
, (CR10R20)nN(R10′
)C(Z)NReRe′
, or (CR10R20)nN(R10′
)C(Z)OR7; and
whereinR6 is independently selected at each occurrence from hydrogen, C1-10 alkyl, C3-7 cycloalkyl, heterocyclyl, heterocyclyl C1-10alkyl, aryl, arylC1-10 alkyl, heteroaryl or heteroarylC1-10 alkyl, wherein each of these moieties, excluding hydrogen are optionally substituted;
R7 is independently selected at each occurrence from C1-6alkyl, aryl, arylC1-6alkyl, heterocyclic, heterocyclylC1-6 alkyl, heteroaryl, or heteroarylC1-6alkyl moiety, and wherein each of these moieties may be optionally substituted;
Re are Re′
are each independently selected at each occurrence from hydrogen, C1-4 alkyl, C3-7 cycloalkyl, C3-7 cycloalkylC1-4alkyl, aryl, aryl-C1-14 alkyl, heterocyclic, heterocyclic C1-4 alkyl, heteroaryl or a heteroaryl C1-4 alkyl moiety;
or Re and Re′
together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 4 to 7 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or nitrogen; and
wherein each of these moieties, excluding hydrogen, may be substituted 1 to 4 times, independently at each occurrence by halogen;
hydroxy;
hydroxy substituted C1-10alkyl;
C1-10alkoxy;
halosubstituted C1-10 alkoxy;
amino, mono &
di-substituted C1-4 alkyl amino, S(O)mRf;
C(O)Rj;
C(O)ORj;
(CR10R20)nN(R10′
)C(Z)OR7;
(CR10R20)nN(R10′
)C(Z)NRdRd′
;
C(O)NR4′
R14′
;
NR4′
C(O)C1-10alkyl;
NR4′
C(O)aryl;
cyano;
nitro;
C1-10 alkyl;
C3-7cycloalkyl;
C3-7cycloalkyl C1-10 alkyl;
halosubstituted C1-10 alkyl;
aryl, aryl C1-4 alkyl, heterocyclic, heterocyclicC1-4 alkyl, heteroaryl, or heteroC1-4alkyl, and wherein these aryl, heterocyclic, and heteroaryl containing moieties may be optionally substituted one to two times independently at each occurrence by halogen, C1-4 alkyl, hydroxy, hydroxy substituted C1-4 alkyl, C1-10 alkoxy, S(O)malkyl, amino, mono &
di-substituted C1-4 alkyl amino, C1-4 alkyl, or CF3;
Rf is independently selected at each occurrence from C1-10alkyl, aryl, aryl C1-10alkyl, heteroaryl, heteroaryl C1-10alkyl, heterocyclic, or a heterocyclic C1-10alkyl moiety, and wherein these moieties may all be optionally substituted;
R4′
and R14′
are each independently selected at each occurrence from hydrogen or C1-4 alkyl, or R4′
and R14′
can cyclize together with the nitrogen to which they are attached to form a 5 to 7 membered ring which optionally contains an additional heteroatom selected from oxygen, sulfur or NR9′
;
Rj is independently selected at each occurrence from hydrogen, C1-4alkyl, aryl, aryl C1-4alkyl, heteroaryl, heteroaryl C1-4alkyl, heterocyclic, or a heterocyclic C1-4alkyl moiety, and wherein these moieties, excluding hydrogen, may be optionally substituted; and
n is 0 or an integer having a value of 1 to 10, and is independently selected at each occurrence.
- moieties, excluding hydrogen, are optionally substituted 1 to 4 times, independently, at each occurrence, by C1-10 alkyl, halo-substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C3-7cycloalkylC1-10alkyl, C5-7cycloalkenyl, C5-7 cycloalkenylC1-10 alkyl, halogen, —
-
46. The compound according to claim 45 wherein R2′
- is a heterocyclic ring or heterocyclic alkyl substituted one or more times, independently by C1-10 alkyl, aryl, arylalkyl, (CR10R20)nNReRe′
, or (CR10R20)nN(R10′
)C(Z)OR7.
- is a heterocyclic ring or heterocyclic alkyl substituted one or more times, independently by C1-10 alkyl, aryl, arylalkyl, (CR10R20)nNReRe′
-
47. The compound according to claim 22 wherein the (CH2)nN(R2′
- )(R2″
) moiety is 1-(phenylmethyl)-4-piperidinamine, 2-[4-(phenylmethyl)-1-piperazinyl]ethylamine, 2-(1-piperidinyl)ethylamine, 2-(1-methyl-2-pyrrolidinyl)ethylamine, 1-[(phenylmethyl)-3-pyrrolidinyl]amine, 3-[(1-pyrrolidinyl)propyl]amine, 3-[(hexahydro-1H-azepin-1-yl)propyl]amine, (1-methyl-4-piperidinyl)amine, 3-[(4-morpholinyl)propyl]amine, 3-[(2-oxo-1-pyrrolidinyl)propyl]amine, 2-[(4-morpholinyl)ethyl]amine, 2-[(1-pyrrolidinyl)ethyl]amine, or [(1-ethyl-2-pyrrolidinyl)methyl]amine.
- )(R2″
-
48. The compound according to claim 45 wherein R2′
- is a C1-10 alkyl substituted by (CR10R20)nNReRe′
or (CR10R20)nNReRe′
C1-4alkylNReRe′
.
- is a C1-10 alkyl substituted by (CR10R20)nNReRe′
-
49. The compound according to claim 48 wherein Re and Re′
- are independently selected from methyl, ethyl, isopropyl, n-butyl, or t-butyl, and n=0.
-
50. The compound according to claim 22 wherein (CH2)nN(R2′
- )(R2″
) is 3-(dimethylamino)propyl(methyl)amine, 3-(diethylamino)propylamine, propylamine, (2,2-dimethylpropyl)amine, (2-hydroxypropyl)amino, 2-(dimethylamino)ethylamine, 2-(dimethylamino)ethyl(methyl)amine, 3-(dimethylamino)propylamine, 2-(dimethylamino)ethyl(methyl)amine, 3-(diethylamino)propylamine, 2-(methylamino)ethylamine, [(1-methylethyl)amino]ethylamine, 3-(diethylamino)propylamine, 3-(dibutylamino)propylamine, 3-[(1-methylethyl)amino]propylamine, 3-(1,1-dimethylethyl)aminopropylamine, 3-(dimethylamino)-2,2-dimethylpropylamine, 4-(diethylamino)-1-methylbutylamine, or 3-[[3-(dimethylamino)propyl]-(methyl)amino]propyl(methyl)amine.
- )(R2″
-
51. The compound according to claim 1 wherein R3 is an optionally substituted C1-10 alkyl, C3-7 cycloalkyl, C3-7 cycloalkylalkyl, or aryl.
-
52. The compound according to claim 51 wherein R3 is optionally substituted one or more times, independently at each occurrence, with halogen, nitro, C1-10 alkyl, halo-substituted C1-10 alkyl, C2-10 alkenyl, C2-10alkynyl, C3-7cycloalkyl, C3-7cycloalkylC1-10 alkyl, C5-7cycloalkenyl, C5-7cycloalkenylC1-10 alkyl, (CR10R20)nOR6, (CR10R20)nSH, (CR10R20)nS(O)mR7, (CR10R20)nN(R10′
- )S(O)2R7, (CR10R20)nNR16R26, (CR10R20)nCN, (CR10R20)nS(O)2NR16R26, (CR10R20)nC(Z)R6, (CR10R20)nOC(Z)R6, (CR10R20)nC(Z)OR6, (CR10R20)nC(Z)NR16R26, (CR10R20)nN(R10′
)C(Z)R6, (CR10R20)nN(R10′
)C(═
N(R10′
))NR16R26, (CR10R20)nOC(Z)NR16R26, (CR10R20)nN(R10′
)C(Z)NR16R26, or (CR10R20)nN(R10)C(Z)OR7; and
whereinR6 is independently selected at each occurrence from hydrogen, C1-10 alkyl, C3-7 cycloalkyl, heterocyclyl, heterocyclyl C1-10alkyl, aryl, arylC1-10 alkyl, heteroaryl or heteroarylC1-10 alkyl, wherein each of these moieties, excluding hydrogen are optionally substituted;
R7 is independently selected at each occurrence from C1-6alkyl, aryl, arylC1-6alkyl, heterocyclic, heterocyclylC1-6 alkyl, heteroaryl, or heteroarylC1-6alkyl moiety, and wherein each of these moieties may be optionally substituted; and
n is 0 or an integer having a value of 1 to 10, and is independently selected at each occurrence.
- )S(O)2R7, (CR10R20)nNR16R26, (CR10R20)nCN, (CR10R20)nS(O)2NR16R26, (CR10R20)nC(Z)R6, (CR10R20)nOC(Z)R6, (CR10R20)nC(Z)OR6, (CR10R20)nC(Z)NR16R26, (CR10R20)nN(R10′
-
53. The compound according to claim 52 wherein the R3 is an optionally substituted aryl.
-
54. The compound according to claim 53 wherein the aryl is a phenyl substituted one or more times independently at each occurrence by halogen, (CR10R20)nOR6, C1-10 alkyl, (CR10R20)nNR16R26, or halosubstituted alkyl.
-
55. The compound according claim 54 wherein the phenyl is substituted one or more times independently by halogen, hydroxy, alkoxy, amino, alkyl, or CF3.
-
56. The compound according to claim 55 wherein the phenyl is disubstituted independently at each occurrence by halogen or methyl.
-
57. The compound according to claim 56 wherein R3 is 2,6-difluorophenyl.
-
58. The compound according to claim 1 wherein R3 is a 2,6-difluoro phenyl, R1′
- is independently selected at each occurrence from hydrogen, fluorine, or methyl;
g is 1 or 2;
R1 is C(Z)N(R10′
)(CR10R20)vRb, Rb is C1-10 alkyl or an optionally substituted aryl;
X is (CH2)nN(R2′
)(R2″
), n is 0, and R2′
is an alkyl substituted by (CR10R20)nNReRe′
.
- is independently selected at each occurrence from hydrogen, fluorine, or methyl;
-
59. The compound according to claim 58 wherein the compound is of Formula (Ic), Re and Re′
- are independently selected from methyl, ethyl, isopropyl, n-butyl, or t-butyl, Rb is C1-10 alkyl, g is 1;
C(Z)N(R10′
)(CR10R20)vRb, and Z is oxygen, R10, is hydrogen, and v=0.
- are independently selected from methyl, ethyl, isopropyl, n-butyl, or t-butyl, Rb is C1-10 alkyl, g is 1;
-
60. The compound according to claim 1, which is:
-
1,1-Dimethylethyl {1-[4-{5-[(cyclobutylamino)carbonyl]-2-methylphenyl}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-2-yl]-4-piperidinyl}carbamate;
3-[2-(4-Amino-1-piperidinyl)-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-cyclobutyl-4-methylbenzamide;
1,1-Dimethylethyl {1-[4-(5-{[(cyclopropylmethyl)amino]carbonyl}-2-methylphenyl)-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-2-yl]-4-piperidinyl}carbamate;
3-[2-(4-Amino-1-piperidinyl)-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(cyclopropylmethyl)-4-methylbenzamide;
3-[2-(4-Amino-1-piperidinyl)-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-[2-(4-fluorophenyl)ethyl]-4-methylbenzamide;
1,1-Dimethylethyl(1-{8-(2,6-difluorophenyl)-4-[5-({[2-(4-fluorophenyl)ethyl]amino}carbonyl)-2-methylphenyl]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-2-yl}-4-piperidinyl)carbamate;
3-[2-[(2-Aminoethyl)(methyl)amino]-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(cyclopropylmethyl)-4-methylbenzamide;
N-(Cyclopropylmethyl)-3-(8-(2,6-difluorophenyl)-2-{[2-(methylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methylbenzamide;
N-(Cyclopropylmethyl)-3-[8-(2,6-difluorophenyl)-7-oxo-2-(4-piperidinylamino)-5,6,7,8-tetrahydropyrimido[4,5-]pyrimidin-4-yl]-4-methylbenzamide;
1,1-Dimethylethyl 4-{[4-(5-{[(cyclopropylmethyl)amino]carbonyl}-2-methylphenyl)-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-2-yl]amino}-1-piperidinecarboxylate;
N-(3-{8-(2,6-Difluorophenyl)-7-oxo-2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methylphenyl)-3-thiophenecarboxamide;
3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-(4-fluorophenyl)-4-methylbenzamide;
3-{8-(2,6-difluorophenyl)-2-[[3-(dimethylamino)-propyl](methyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-N-(4-fluorophenyl)-4-methylbenzamide;
N-{3-[8-(2,6-difluorophenyl)-2-(methyloxy)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-thiophenecarboxamide;
N-{3-[2-(4-amino-1-piperidinyl)-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-thiophenecarboxamide;
N-{3-[8-(2,6-difluorophenyl)-2-(dimethylamino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-thiophenecarboxamide;
N-{3-[8-(2,6-difluorophenyl)-2-(ethyloxy)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-thiophenecarboxamide;
N-{3-[8-(2,6-difluorophenyl)-2-(methylamino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-thiophenecarboxamide;
3-[2-(4-Amino-1-piperidinyl)-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(phenylmethyl)benzamide;
3-{8-(2,6-Difluorophenyl)-7-oxo-2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methyl-N-(phenylmethyl)benzamide;
3-{8-(2,6-Difluorophenyl)-2-[[3-(dimethylamino)propyl](methyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-]pyrimidin-4-yl}-4-methyl-N-(phenylmethyl)benzamide;
3-(8-(2,6-Difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(phenylmethyl)benzamide;
3-(8-(2,6-Difluorophenyl)-2-{[2-(methylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(phenylmethyl)benzamide;
1,1-Dimethylethyl(2-{[8-(2,6-difluorophenyl)-4-(2-methyl-5-{[(phenylmethyl)amino]carbonyl}phenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-2-yl]amino}ethyl)methylcarbamate;
3-[8-(2,6-Difluorophenyl)-2-({2-[(1-methylethyl)amino]ethyl}amino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(phenylmethyl)benzamide;
3-[8-(2,6-Difluorophenyl)-7-oxo-2-(4-piperidinylamino)-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(phenylmethyl)benzamide;
1,1-Dimethylethyl 4-{[8-(2,6-difluorophenyl)-4-(2-methyl-5-{[(phenylmethyl)amino]carbonyl}phenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-2-yl]amino}-1-piperidinecarboxylate;
3-{8-(2,6-Difluorophenyl)-2-[(1-methyl-4-piperidinyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methyl-N-(phenylmethyl)benzamide;
N-(3-{8-(2,6-difluorophenyl)-7-oxo-2-[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-5,6,7,8-tetrahydropyrimido[4,5-]pyrimidin-4-yl}-4-methylphenyl)-3-fluoro-4-methylbenzamide;
N-{3-[2-(4-amino-1-piperidinyl)-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-fluoro-4-methylbenzamide;
N-{3-[8-(2,6-difluorophenyl)-2-(ethyloxy)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-fluoro-4-methylbenzamide;
N-(3-{8-(2,6-difluorophenyl)-2-[(1-methylethyl)oxy]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methylphenyl)-3-fluoro-4-methylbenzamide;
N-{3-[8-(2,6-difluorophenyl)-7-oxo-2-(4-piperidinylamino)-5,6,7,8-tetrahydropyrimido[4,5-]pyrimidin-4-yl]-4-methylphenyl}-3-fluoro-4-methylbenzamide;
1,1-dimethylethyl 4-{[8-(2,6-difluorophenyl)-4-(5-{[(3-fluoro-4-methylphenyl)carbonyl]amino}-2-methylphenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-]pyrimidin-2-yl]amino}-1-piperidinecarboxylate;
N-{3-[8-(2,6-difluorophenyl)-2-(dimethylamino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-fluoro-4-methylbenzamide;
3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide; and
a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.
-
-
61. The compound according to claim 1 which is:
-
N-(Cyclopropylmethyl)-3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylbenzamide;
N-(Cyclopropylmethyl)-3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylbenzamide;
N-{3-[8-(2,6-Difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-thiophenecarboxamide;
3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide;
3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide;
N-{3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-thiophenecarboxamide;
N-{3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-thiophenecarboxamide;
3-[8-(2,6-Difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(phenylmethyl)benzamide;
3-[8-(2,6-Difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(phenylmethyl)benzamide;
N-{3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-fluoro-4-methylbenzamide;
N-{3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-fluoro-4-methylbenzamide;
3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide;
3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide; and
a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.
-
-
62. A compound according to claim 1 which is
N-{3-[2-(4-amino-1-piperidinyl)-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-fluoro-4-methylbenzamide N-{3-[8-(2,6-difluorophenyl)-2-(ethyloxy)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-fluoro-4-methylbenzamide N-(3-{8-(2,6-difluorophenyl)-2-[(1-methylethyl)oxy]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methylphenyl)-3-fluoro-4-methylbenzamide N-{3-[8-(2,6-difluorophenyl)-7-oxo-2-(4-piperidinylamino)-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-fluoro-4-methylbenzamide N-{3-[8-(2,6-difluorophenyl)-2-(dimethylamino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-fluoro-4-methylbenzamide 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide 3-[8-(2,6-difluorophenyl)-2-({2-[(1-methylethyl)amino]ethyl}amino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide 3-(8-(2,6-difluorophenyl)-2-{[2-(methylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-(4-fluorophenyl)-4-methylbenzamide 3-{8-(2,6-difluorophenyl)-2-[[2-(dimethylamino)ethyl](methyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-N-(4-fluorophenyl)-4-methylbenzamide 3-{8-(2,6-difluorophenyl)-2-[4-(methylamino)-1-piperidinyl]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-N-(4-fluorophenyl)-4-methylbenzamide 3-{8-(2,6-difluorophenyl)-2-[[3-(dimethylamino)propyl](methyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methyl-N-(1-methylethyl)benzamide 3-[8-(2,6-difluorophenyl)-2-({2-[(1-methylethyl)amino]ethyl}amino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide 3-{8-(2,6-difluorophenyl)-2-[[2-(dimethylamino)ethyl](methyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-4-methyl-N-(1-methylethyl)benzamide 3-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(1-methylethyl)benzamide 3-(8-(2,6-difluorophenyl)-2-{[2-(methylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(1-methylethyl)benzamide 3-{8-(2,6-difluorophenyl)-2-[(1-methyl-4-piperidinyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-N-(4-fluorophenyl)-4-methylbenzamide 3-(8-(2,6-difluorophenyl)-2-{[3-(dimethylamino)propyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-4-methyl-N-(1-methylethyl)benzamide 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide 3-(8-(2,6-difluorophenyl)-2-{[3-(dimethylamino)propyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-(4-fluorophenyl)-4-methylbenzamide 3-[2-{[3-(diethylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide 3-{8-(2,6-difluorophenyl)-2-[(1H-imidazol-2-ylmethyl)amino]-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl}-N-(4-fluorophenyl)-4-methylbenzamide 3-[2-{[3-(dibutylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide 3-[8-(2,6-difluorophenyl)-2-({3-[(1-methylethyl)amino]propyl}amino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide 3-[8-(2,6-difluorophenyl)-2-({3-[(1,1-dimethylethyl)amino]propyl}amino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide 3-[2-{[3-(dibutylamino)propyl]amino}-8-(2,6-difluorophenyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide 3-[8-(2,6-difluorophenyl)-2-({3-[(1-methylethyl)amino]propyl}amino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide 3-[8-(2,6-difluorophenyl)-2-({3-[(1,1-dimethylethyl)amino]propyl}amino)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide; - and
a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.
- and
-
63. A compound of general formula (I) or (Ia) according to claim 1, as described in any of Examples 1 to 230 herein, or a tautomer, diastereomer, enantiomer, or salt thereof.
-
65. A pharmaceutical composition comprising an effective amount of a compound, a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof according to claim 1 and a pharmaceutically acceptable carrier or diluent.
-
66. A pharmaceutical composition comprising an effective amount of a compound, or pharmaceutically acceptable salt, solvate or physiologically functional derivative according to claim 1, in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients, for administration by intravenous, intramuscular, subcutaneous, intranasal, oral inhalation, intrarectal, intravaginal or intraperitoneal means.
-
67. A method of treating an inflammatory component of a CSBP/RK/p38 kinase mediated disease in a mammal in need thereof, which method comprises administering to said mammal an effective amount of a compound, a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, according to claim 1.
-
68. The method according to claim 67 wherein the CSBP/RK/p38 kinase mediated disease is psoriatic arthritis, Reiter'"'"'s syndrome, gout, traumatic arthritis, rubella arthritis, acute synovitis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic condition, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, cerebral malaria, meningitis, ischemic and hemorrhagic stroke, neurotrauma/closed head injury, asthma, adult respiratory distress syndrome, chronic pulmonary inflammatory disease, chronic obstructive pulmonary disease (COPD), silicosis, pulmonary sarcososis, bone resorption disease, osteoporosis, restenosis, cardiac and brain and renal reperfusion injury, congestive heart failure, coronary arterial bypass grafting (CABG) surgery, thrombosis, glomerularnephritis, chronic renal failure, diabetes, diabetic retinopathy, macular degeneration, atheroschlerosis, graft vs. host reaction, allograft rejection, inflammatory bowel disease, Crohn'"'"'s disease, ulcerative colitis, neurodegenrative disease, muscle degeneration, atheroschlerosis, diabetic retinopathy, macular degeneration, tumor growth and metastasis, angiogenic disease, influenza induced pneumonia, eczema, contact dermatitis, psoriasis, sunburn, or conjunctivitis.
-
69. A method of treating the inflammation associated with the common cold or a respiratory viral infection caused by human rhinovirus (HRV), other enteroviruses, coronavirus, influenza virus, parainfluenza virus, respiratory syncytial virus, or adenovirus in a human in need thereof which method comprises administering to said human an effective amount of a compound, a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof according to claim 1.
-
70. The method according to claim 69 wherein the respiratory viral infection exacerbates asthma, exacerbates chronic bronchitis, exacerbates chronic obstructive pulmonary disease, exacerbates otitis media, exacerbates sinusitis, or wherein the respiratory viral infection is associated with a secondary bacterial infection, otitis media, sinusitis, or pneumonia.
-
71. A method of treating inflammation in a mammal in need thereof comprising adminisering to said mammal an effective amount of a compound according to claim 1.
-
72. A method of treating traumatic arthritis, rubella arthritis, acute synovitis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic condition, in a mammal in need thereof, comprising administering to said mammal an effective amount of a compound according to claim 1.
-
73. A method of treating, asthma, adult respiratory distress syndrome, chronic pulmonary inflammatory disease, or chronic obstructive pulmonary disease (COPD) in a mammal in need thereof, comprising administering to said mammal an effective amount of a compound according to claim 1.
-
74. A method of treating atherosclerosis, inflammatory bowel disease, Crohn'"'"'s disease, or ulcerative colitis in a mammal in need thereof, comprising administering to said mammal an effective amount of a compound according to claim 1.
-
81. A compound of the formula:
-
82. The compound according to claim 81 wherein R3 is a 2,6-difluorophenyl, and Rg is methyl.
-
83. The compound according to claim 81 which is
3-[8-(2,6-Difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-4-methylbenzoic acid; -
N-(Cyclopropylmethyl)-3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylbenzamide;
N-(Cyclopropylmethyl)-3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl]-4-methylbenzamide;
3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide;
3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-N-(4-fluorophenyl)-4-methylbenzamide;
N-{3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-thiophenecarboxamide;
N-{3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-thiophenecarboxamide;
3-[8-(2,6-Difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-4-methyl-N-(phenylmethyl)benzamide;
3-[8-(2,6-Difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-4-methyl-N-(phenylmethyl)benzamide;
N-{3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-fluoro-4-methylbenzamide;
N-{3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-4-methylphenyl}-3-fluoro-4-methylbenzamide;
3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide;
3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-4-methyl-N-propylbenzamide;
3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide;
3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-4-methyl-N-(1-methylethyl)benzamide;
3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-4-methyl-N-1,3-thiazol-2-ylbenzamide;
3-[8-(2,6-difluorophenyl)-2-(methylsulfinyl)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-4-methyl-N-1,3-thiazol-2-ylbenzamide;
3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-N,N,4-trimethylbenzamide;
3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-N,N,4-trimethylbenzamide;
3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-N,4-dimethylbenzamide;
3-[8-(2,6-difluorophenyl)-2-(methylsulfonyl)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-N,4-dimethylbenzamide;
or3-[8-(2,6-difluorophenyl)-2-(methylthio)-7-oxo-5,6,7,8-tetrahydropyrimido-[4,5-d]pyrimidin-4-yl]-4-methylbenzoic acid.
-
-
86. The compound according to claim 81 which is Formula (Id), or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.
-
95. The compound according to claim 81 wherein X is (CH2)nNR4R14, or (CH2)nN(R2′
- )(R2″
).
- )(R2″
-
96. The compound according to claim 95 wherein X is (CH2)nNR4R14, and R4 and R14 are independently selected from hydrogen, optionally substituted C1-10 alkyl, optionally substituted aryl, optionally substituted aryl-C1-4 alkyl, optionally substituted heterocyclic, optionally substituted heterocylic C1-4 alkyl, optionally substituted heteroaryl or optionally substituted heteroaryl C1-4 alkyl.
-
98. The compound according to claim 95 wherein X is (CH2)nNR4R14 and one of R4 and R14 is an optionally substituted heteroaryl C1-4 alkyl, and the heteroaryl moiety is selected from thienyl, pyrrolyl, oxazolyl, thiazolyl, isoxazolyl, isothiazolyl, imidazolyl, pyrazolyl, triazolyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzoxazolyl, benzimidazolyl, and benzothiazolyl.
-
99. The compound according to claim 95 wherein X is (CH2)nNR4R14 and one of R4 and R14 is a heterocyclic C1-4 alkyl moiety selected from tetrahydropyrrole, tetrahydropyran, tetrahydrofuran, pyrrolinyl, pyrrolidinyl, imidazolinyl, imidazolidinyl, indolinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, diazepinyl, piperazinyl, and morpholino.
-
100. The compound according to claim 95 wherein X is (CH2)nNR4R4 and R4 and R14 together with the nitrogen cyclize to form an optionally substituted ring selected from pyrrolidine, piperidine, piperazine, and morpholine.
-
2. The compound according to claim 1 which is Formula (I), or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.
-
64. A compound as defined in any one of Examples 1 to 230 or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.
-
75. A compound of the formula:
- View Dependent Claims (76, 77, 78, 79)
-
76. A compound according to claim 75 wherein:
-
4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-1,3-thiazol-2-ylbenzamide 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)benzoic acid 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-(1-methylethyl)benzamide 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-propylbenzamide 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-phenylbenzamide 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-(4-fluorophenyl)benzamide 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N,N-dimethylbenzamide 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-methylbenzamide 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)benzamide 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-3-methyl-N-(1-methylethyl)benzamide 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-3-methylbenzoic acid 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-3-methyl-N-propylbenzamide 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-3-methyl-N-phenylbenzamide 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N-(4-fluorophenyl)-3-methylbenzamide 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N,N,3-trimethylbenzamide 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-N,3-dimethylbenzamide 4-(8-(2,6-difluorophenyl)-2-{[2-(dimethylamino)ethyl]amino}-7-oxo-5,6,7,8-tetrahydropyrimido[4,5-d]pyrimidin-4-yl)-3-methylbenzamide;
ora pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.
-
-
77. A pharmaceutical composition comprising an effective amount of a compound, or pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof according to claim 75, in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients.
-
78. A pharmaceutical composition comprising an effective amount of a compound, or pharmaceutically acceptable salt, solvate or physiologically functional derivative according to claim 75 in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients, for administration by intravenous, intramuscular, subcutaneous, intranasal, oral inhalation, intrarectal, intravaginal or intraperitoneal means.
-
79. A method of treating an inflammatory component of a CSBP/RK/p38 kinase mediated disease in a mammal in need thereof, which method comprises administering to said mammal an effective amount of a compound, a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, according to claim 75.
-
76. A compound according to claim 75 wherein:
-
80. A compound of the formula:
-
84. A compound of the formula:
- View Dependent Claims (85, 87, 88, 89, 90, 91, 92, 93, 94, 97, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133)
-
85. The compound according to claim 84 which is Formula (Ic), or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.
-
87. The compound according to claim 84 wherein R1 is C(Z)N(R11′
- )(CR10R20)vRb.
-
88. The compound according to claim 84 wherein Rb is an optionally substituted heteroaryl, heteroarylalkyl, heterocyclic, or heterocyclicalkyl.
-
89. The compound according to claim 88 wherein Rb is an optionally substituted heteroaryl, or heteroarylalkyl.
-
90. The compound according to claim 84 wherein Rb is a 1,3-thiazol-2-yl, 5-methyl-1,3-thiazol-2-yl, isoquinoline, 3-thiophene, indol-5-yl, pyridin-3-yl, pyridine-4-yl, indazolyl, benzothiazolyl, 2-methyl-1,3-benzothiazol-5-yl, pyrazol-3-yl, 4-morpholino, 2-furanyl, 2-furanylmethyl, 2-thienyl, 2-thienylmethyl, tetrahydro-2H-pyran-4yl, tetrahydro-2H-pyran-4-yl methyl, tetrahydro-2-furanyl, or tetrahydro-2-furanylmethyl, 2,3-dihydro-1,4-benzodioxin-6-yl, 1H-imidazol-4-yl or 1H-imidazol-4-yl-ethyl.
-
91. The compound according to claim 84 wherein Rb is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl, or cyclopentylmethyl.
-
92. The compound according to claim 84 wherein the R1′
- is independently selected from halogen, C1-4 alkyl, or halo-substituted-C1-4 alkyl.
-
93. The compound according to claim 92 wherein the substituents are independently fluorine, methyl, or CF3.
-
94. The compound according to claim 84 wherein g is 1.
-
97. The compound according to claim 93 wherein the C1-10 alkyl may be substituted one or more times, independently at each occurrence with NR4′
- R14′
;
halogen, hydroxy, alkoxy, C(O)NR4′
R14′
;
or NR4′
C(O)C1-10alkyl.
- R14′
-
101. The compound according to claim 92 wherein the R4 and R14 cyclized ring is optionally substituted one or more times independently by an optionally substituted alkyl, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted heterocyclic, (CR10R20)nN(R10′
- )C(Z)OR7, or NR4′
R14′
,
- )C(Z)OR7, or NR4′
-
102. The compound according to claim 101 wherein the optional substituents are selected from phenyl, pyrrolidinyl, morpholino, piperazinyl, 4-methyl-1-piperazinyl, piperidinyl, 2-oxo-2,3-dihydro-1H-benzimidazol-1-yl, 5-chloro-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl, diphenylmethyl, methyl, ethyl, propyl, butyl, amino, methylamino, and dimethylamino.
-
103. The compound according to claim 84 wherein X is R2 and R2 is an optionally substituted heterocyclic or heterocyclic alkyl ring substituted one or more times independently at each occurrence by an optionally substituted heterocyclic, heterocyclic C1-10 alkyl, aryl, aryl C1-10 alkyl, C1-10 alkyl, (CR10R20)nNReRe′
- , or (CR10R20)nN(R10′
)C(Z)OR7.
- , or (CR10R20)nN(R10′
-
104. The compound according to claim 103 wherein R2 is selected from 1,4′
- -bipiperin-1-yl, 4-methyl-1,4′
-bipiperin-1-yl, 4-piperidinylamino, 4-amino-1-piperidinyl, 2,2,6,6-tetramethyl-4-piperidinyl)amino, 4-methyl-1-piperazinyl, (4-morpholinyl)-1-piperidinyl, (4-methyl-1-piperazinyl)-1-piperidinyl, 4-ethyl-1-piperazinyl, (2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinyl, 5-chloro-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidinyl, 4-(1-pyrrolidinyl)-1-piperidinyl, 4-(diphenylmethyl)-1-piperazinyl, 4-methylhexahydro-1H-1,4-diazepin-1-yl, 4-propyl-1-piperazinyl, or 4-butyl-1-piperazinyl.
- -bipiperin-1-yl, 4-methyl-1,4′
-
105. The compound according to claim 84 wherein R2 is optionally substituted one or more times, independently at each occurrence, with C1-10 alkyl, halo-substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C3-7cycloalkylC1-10alkyl, C5-7cycloalkenyl, C5-7 cycloalkenyl C1-10 alkyl, halogen, —
- C(O), cyano, nitro, aryl, aryl C1-10 alkyl, heterocyclic, heterocyclic C1-10 alkyl, heteroaryl, heteroaryl C1-10 alkyl, (CR10R20)nOR6, (CR10R20)nSH, (CR10R20)nS(O)mR7, (CR10R20)nN(R10′
)S(O)2R7, (CR10R20)nNR4R14, (CR10R20)nCN, (CR10R20)nS(O)2NR4R4, (CR10R20)nC(Z)R6, (CR10R20)nOC(Z)R6, (CR10R20)nC(Z)OR6, (CR10R20)nC(Z)NR4R14, (CR10R20)nN(R10′
)C(Z)R6, (CR10R20)nN(R10′
)C(═
N(R10′
))NR4R14, (CR10R20)nC(═
NOR6)NR4R14, (CR10R20)nOC(Z)NR4R14, (CR10R20)nN(R10′
)C(Z)NR4R14, or (CR10R20)nN(R10′
)C(Z)OR7.
- C(O), cyano, nitro, aryl, aryl C1-10 alkyl, heterocyclic, heterocyclic C1-10 alkyl, heteroaryl, heteroaryl C1-10 alkyl, (CR10R20)nOR6, (CR10R20)nSH, (CR10R20)nS(O)mR7, (CR10R20)nN(R10′
-
106. The compound according to claim 105 wherein R2 is an optionally substituted alkyl.
-
107. The compound according to claim 106 wherein the C1-10 alkyl is optionally substituted by (CR10R20)nC(Z)OR6, (CR10R20)nOR6, or (CR10R20)nNR4R14.
-
108. The compound according to claim 84 wherein R2 is (CR10R20)q′
- X1(CR10R20)qC(A1)(A2)(A3), or (CR10R20)q′
C(A1)(A2)(A3).
- X1(CR10R20)qC(A1)(A2)(A3), or (CR10R20)q′
-
109. The compound according to claim 108 wherein X1 is oxygen or N(R10′
- ).
-
110. The compound according to claim 109 wherein at least one of A1, A2 or A3 is substituted by (CR10R20)nOR6, q is 1 or 2, and q′
- is 0.
-
111. The compound according to claim 84 wherein X is (CH2)nN(R2′
- )(R2″
), and R2′
is an optionally substituted C1-10 alkyl, cycloalkyl, heterocyclic, heterocyclyl C1-10 alkyl, heteroarylalkyl.
- )(R2″
-
112. The compound according to claim 111 wherein the R2, moieties, excluding hydrogen, are optionally substituted 1 to 4 times, independently, at each occurrence, by C1-10 alkyl, halo-substituted C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, C3-7 cycloalkyl, C3-7cycloalkylC1-10alkyl, C5-7cycloalkenyl, C5-7 cycloalkenylC1-10 alkyl, halogen, —
- C(O), cyano, nitro, aryl, aryl C1-10 alkyl, aryl, aryl C1-10 alkyl, heterocyclic, heterocyclic C1-10 alkyl, heteroaryl, heteroaryl C1-10 alkyl, (CR10R20)nOR6, (CR10R20)nSH, (CR10R20)nS(O)mR7, (CR10R20)nN(R10′
)S(O)2R7, (CR10R20)nNReRe′
, (CR10R20)nNReRe′
C1-4alkylNReRe′
, (CR10R20)nCN, (CR10R20)nS(O)2NReRe′
, (CR10R20)nC(Z)R6, (CR10R20)nOC(Z)R6, (CR10R20)nC(Z)OR6, (CR10R20)nC(Z)NReRe′
, (CR10R20)nN(R10′
)C(Z)R6, (CR10R20)nN(R10)C(═
N(R10′
))NReRe′
, (CR10R20)nC(═
NOR6)NReRe′
, (CR10R20)nOC(Z)NReRe′
, (CR10R20)nN(R10′
)C(Z)NReRe′
, or (CR10R20)nN(R10′
)C(Z)OR7; and
whereinR6 is independently selected at each occurrence from hydrogen, C1-10alkyl, C3-7 cycloalkyl, heterocyclyl, heterocyclyl C1-10alkyl, aryl, arylC1-10alkyl, heteroaryl or heteroarylC1-10 alkyl, wherein each of these moieties, excluding hydrogen are optionally substituted;
R7 is independently selected at each occurrence from C1-6alkyl, aryl, arylC1-6alkyl, heterocyclic, heterocyclylC1-6 alkyl, heteroaryl, or heteroarylC1-6alkyl moiety, and wherein each of these moieties may be optionally substituted;
Re are Re′
are each independently selected at each occurrence from hydrogen, C1-4 alkyl, C3-7 cycloalkyl, C3-7 cycloalkylC1-4alkyl, aryl, aryl-C1-14 alkyl, heterocyclic, heterocyclic C1-4 alkyl, heteroaryl or a heteroaryl C1-4 alkyl moiety;
or Re and Re′
together with the nitrogen which they are attached form an optionally substituted heterocyclic ring of 4 to 7 members, which ring optionally contains an additional heteroatom selected from oxygen, sulfur or nitrogen; and
wherein each of these moieties, excluding hydrogen, may be substituted 1 to 4 times, independently at each occurrence by halogen;
hydroxy;
hydroxy substituted C1-10alkyl;
C1-10alkoxy;
halosubstituted C1-10 alkoxy;
amino, mono &
di-substituted C1-4 alkyl amino, S(O)mRf;
C(O)Rj;
C(O)ORj;
(CR10R20)nN(R10′
)C(Z)OR7;
(CR10R20)nN(R10′
)C(Z)NRdRd′
;
C(O)NR4′
R14′
;
NR4′
C(O)C1-10alkyl;
NR4′
C(O)aryl;
cyano;
nitro;
C1-10 alkyl;
C3-7cycloalkyl;
C3-7cycloalkyl C1-10 alkyl;
halosubstituted C1-10 alkyl;
aryl, aryl C1-4 alkyl, heterocyclic, heterocyclicC1-4 alkyl, heteroaryl, or heteroC1-4alkyl, and wherein these aryl, heterocyclic, and heteroaryl containing moieties may be optionally substituted one to two times independently at each occurrence by halogen, C1-4 alkyl, hydroxy, hydroxy substituted C1-4 alkyl, C1-10 alkoxy, S(O)malkyl, amino, mono &
di-substituted C1-4 alkyl amino, C1-4 alkyl, or CF3;
Rf is independently selected at each occurrence from C1-10alkyl, aryl, aryl C1-10alkyl, heteroaryl, heteroaryl C1-10alkyl, heterocyclic, or a heterocyclic C1-10alkyl moiety, and wherein these moieties may all be optionally substituted;
R4′
and R14′
are each independently selected at each occurrence from hydrogen or C1-4 alkyl, or R4′
and R14′
can cyclize together with the nitrogen to which they are attached to form a 5 to 7 membered ring which optionally contains an additional heteroatom selected from oxygen, sulfur or NR9′
;
Rj is independently selected at each occurrence from hydrogen, C1-4alkyl, aryl, aryl C1-4alkyl, heteroaryl, heteroaryl C1-4alkyl, heterocyclic, or a heterocyclic C1-4alkyl moiety, and wherein these moieties, excluding hydrogen, may be optionally substituted; and
n is 0 or an integer having a value of 1 to 10, and is independently selected at each occurrence.
- C(O), cyano, nitro, aryl, aryl C1-10 alkyl, aryl, aryl C1-10 alkyl, heterocyclic, heterocyclic C1-10 alkyl, heteroaryl, heteroaryl C1-10 alkyl, (CR10R20)nOR6, (CR10R20)nSH, (CR10R20)nS(O)mR7, (CR10R20)nN(R10′
-
113. The compound according to claim 112 wherein R2′
- is a heterocyclic ring or heterocyclic alkyl substituted one or more times, independently by C1-10 alkyl, aryl, arylalkyl, (CR10R20)nNReRe′
, or (CR10R20)nN(R10′
)C(Z)OR7.
- is a heterocyclic ring or heterocyclic alkyl substituted one or more times, independently by C1-10 alkyl, aryl, arylalkyl, (CR10R20)nNReRe′
-
114. The compound according to claim 84 wherein the (CH2)nN(R2′
- )(R2″
) moiety is 1-(phenylmethyl)-4-piperidinamine, 2-[4-(phenylmethyl)-1-piperazinyl]ethylamine, 2-(1-piperidinyl)ethylamine, 2-(1-methyl-2-pyrrolidinyl)ethylamine, 1-[(phenylmethyl)-3-pyrrolidinyl]amine, 3-[(1-pyrrolidinyl)propyl]amine, 3-[(hexahydro-1H-azepin-1-yl)propyl]amine, (1-methyl-4-piperidinyl)amine, 3-[(4-morpholinyl)propyl]amine, 3-[(2-oxo-1-pyrrolidinyl)propyl]amine, 2-[(4-morpholinyl)ethyl]amine, 2-[(1-pyrrolidinyl)ethyl]amine, or [(1-ethyl-2-pyrrolidinyl)methyl]amine.
- )(R2″
-
115. The compound according to claim 113 wherein R2′
- is an optionally substituted C1-10 alkyl substituted by (CR10R20)nNReRe′
or (CR10R20)nNReRe′
C1-14alkylNReRe.
- is an optionally substituted C1-10 alkyl substituted by (CR10R20)nNReRe′
-
116. The compound according to claim 115 wherein Re and Re′
- are independently selected from methyl, ethyl, isopropyl, n-butyl, or t-butyl.
-
117. The compound according to claim 84 wherein (CH2)nN(R2′
- )(R2″
) is 3-(dimethylamino)propyl(methyl)amine, 3-(diethylamino)propylamine, propylamine, (2,2-dimethylpropyl)amine, (2-hydroxypropyl)amino, 2-(dimethylamino)ethylamine, 2-(dimethylamino)ethyl(methyl)amine, 3-(dimethylamino)propylamine, 2-(dimethylamino)ethyl(methyl)amine, 3-(diethylamino)propylamine, 2-(methylamino)ethylamine, [(1-methylethyl)amino]ethylamine, 3-(diethylamino)propylamine, 3-(dibutylamino)propylamine, 3-[(1-methylethyl)amino]propylamine, 3-(1,1-dimethylethyl)aminopropylamine, 3-(dimethylamino)-2,2-dimethylpropylamine, 4-(diethylamino)-1-methylbutylamine, or 3-[[3-(dimethylamino)propyl]-(methyl)amino]propyl(methyl)amine.
- )(R2″
-
118. The compound according to claim 84 wherein R3 is an optionally substituted C1-10 alkyl, C3-7 cycloalkyl, C3-7 cycloalkylalkyl, or aryl.
-
119. The compound according to claim 118 wherein R3 is optionally substituted one or more times, independently at each occurrence, with C1-10 alkyl, halo-substituted C1-10 alkyl, C2-10 alkenyl, C2-10alkynyl, C3-7cycloalkyl, C3-7cycloalkylC1-10alkyl, C5-7cycloalkenyl, C5-7cycloalkenylC1-10 alkyl, halogen, cyano, nitro, (CR10R20)nOR6, (CR10R20)nSH, (CR10R20)nS(O)mR7, (CR10R20)nN(R10′
- )S(O)2R7, (CR10R20)nNR4R14, (CR10R20)nCN, (CR10R20)nS(O)2NR4R14, (CR10R20)nC(Z)R6, (CR10R20)nOC(Z)R6, (CR10R20)nC(Z)OR6, (CR10R20)nC(Z)NR4R14, (CR10R20)nN(R10′
)C(Z)R6, (CR10R20)nN(R10)C(═
N(R10))NR4R14, (CR10R20)nOC(Z)NR4R14, (CR10R20)nN(R10′
)C(Z)NR4R14, or (CR10R20)nN(R10′
)C(Z)OR7; and
whereinR6 is independently selected at each occurrence from hydrogen, C1-10 alkyl, C3-7 cycloalkyl, heterocyclyl, heterocyclyl C1-10alkyl, aryl, arylC1-10 alkyl, heteroaryl or heteroarylC1-10 alkyl, wherein each of these moieties, excluding hydrogen are optionally substituted;
R7 is independently selected at each occurrence from C1-6alkyl, aryl, arylC1-6alkyl, heterocyclic, heterocyclylC1-6 alkyl, heteroaryl, or heteroarylC1-6alkyl moiety, and wherein each of these moieties may be optionally substituted; and
n is 0 or an integer having a value of 1 to 10, and is independently selected at each occurrence.
- )S(O)2R7, (CR10R20)nNR4R14, (CR10R20)nCN, (CR10R20)nS(O)2NR4R14, (CR10R20)nC(Z)R6, (CR10R20)nOC(Z)R6, (CR10R20)nC(Z)OR6, (CR10R20)nC(Z)NR4R14, (CR10R20)nN(R10′
-
120. The compound according to claim 119 wherein the R3 is an optionally substituted aryl.
-
121. The compound according to claim 120 wherein the aryl is a phenyl substituted one or more times independently at each occurrence by halogen, (CR10R20)nOR6, C1-10 alkyl, (CR10R20)nNR16R26, or halosubstituted alkyl.
-
122. The compound according to claim 121 wherein the phenyl is substituted one or more times independently by halogen, hydroxy, alkoxy, amino, alkyl, or CF3.
-
123. The compound according to claim 122 wherein the phenyl is disubstituted independently at each occurrence by halogen or methyl.
-
124. The compound according claim 123 wherein the phenyl ring is substituted one or more times independently by halogen.
-
125. The compound according to claim 124 wherein R3 is a 2,6-difluorophenyl.
-
126. A pharmaceutical composition comprising an effective amount of a compound, a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof according to claim 84 and a pharmaceutically acceptable carrier or diluent.
-
127. A pharmaceutical composition comprising an effective amount of a compound, or pharmaceutically acceptable salt, solvate or physiologically functional derivative according to claim 84, in admixture with one or more pharmaceutically acceptable carriers, diluents or excipients, for administration by intravenous, intramuscular, subcutaneous, intranasal, oral inhalation, intrarectal, intravaginal or intraperitoneal means.
-
128. A method of treating an inflammatory component of a CSBP/RK/p38 kinase mediated disease in a mammal in need thereof, which method comprises administering to said mammal an effective amount of a compound, a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, according to claim 84.
-
129. The method according to claim 128 wherein the CSBP/RK/p38 kinase mediated disease is psoriatic arthritis, Reiter'"'"'s syndrome, gout, traumatic arthritis, rubella arthritis, acute synovitis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic condition, sepsis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, cerebral malaria, meningitis, ischemic and hemorrhagic stroke, neurotrauma/closed head injury, asthma, adult respiratory distress syndrome, chronic pulmonary inflammatory disease, chronic obstructive pulmonary disease (COPD), silicosis, pulmonary sarcososis, bone resorption disease, osteoporosis, restenosis, cardiac and brain and renal reperfusion injury, congestive heart failure, coronary arterial bypass grafting (CABG) surgery, thrombosis, glomerularnephritis, chronic renal failure, diabetes, diabetic retinopathy, macular degeneration, atheroschlerosis, graft vs. host reaction, allograft rejection, inflammatory bowel disease, Crohn'"'"'s disease, ulcerative colitis, neurodegenrative disease, muscle degeneration, atheroschlerosis, diabetic retinopathy, macular degeneration, tumor growth and metastasis, angiogenic disease, influenza induced pneumonia, eczema, contact dermatitis, psoriasis, sunburn, or conjunctivitis.
-
130. A method of treating inflammation in a mammal in need thereof comprising adminisering to said mammal an effective amount of a compound according to claim 84.
-
131. A method of treating, traumatic arthritis, rubella arthritis, acute synovitis, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic condition, in a mammal in need thereof, comprising administering to said mammal an effective amount of a compound according to claim 84.
-
132. A method of treating, asthma, adult respiratory distress syndrome, chronic pulmonary inflammatory disease, or chronic obstructive pulmonary disease (COPD) in a mammal in need thereof, comprising administering to said mammal an effective amount of a compound according to claim 84.
-
133. A method of treating atherosclerosis, inflammatory bowel disease, Crohn'"'"'s disease, or ulcerative colitis, in a mammal in need thereof, comprising administering to said mammal an effective amount of a compound according to claim 84.
-
85. The compound according to claim 84 which is Formula (Ic), or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.
Specification
- Resources
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeGlaxo Group Limited (Glaxosmithkline Holdings Ltd.)
-
Original AssigneeGlaxo Group Limited (Glaxosmithkline Holdings Ltd.)
-
InventorsCallahan, James F., Yan, Hongxing, Wan, Zehong
-
Granted Patent
-
Time in Patent OfficeDays
-
Field of Search
-
US Class Current514/262.100
-
CPC Class CodesA61P 1/00 Drugs for disorders of the ...A61P 1/04 for ulcers, gastritis or re...A61P 11/00 Drugs for disorders of the ...A61P 11/06 AntiasthmaticsA61P 13/12 of the kidneysA61P 17/00 Drugs for dermatological di...A61P 17/06 AntipsoriaticsA61P 19/02 for joint disorders, e.g. a...A61P 19/06 Antigout agents, e.g. antih...A61P 19/08 for bone diseases, e.g. rac...A61P 19/10 for osteoporosisA61P 21/00 Drugs for disorders of the ...A61P 25/00 Drugs for disorders of the ...A61P 25/28 for treating neurodegenerat...A61P 27/02 Ophthalmic agentsA61P 29/00 Non-central analgesic, anti...A61P 3/10 for hyperglycaemia, e.g. an...A61P 31/04 Antibacterial agentsA61P 33/06 AntimalarialsA61P 35/00 Antineoplastic agentsA61P 35/04 : specific for metastasisA61P 37/00 : Drugs for immunological or ...A61P 37/06 : Immunosuppressants, e.g. dr...A61P 43/00 : Drugs for specific purposes...A61P 7/02 : Antithrombotic agents; Anti...A61P 9/00 : Drugs for disorders of the ...A61P 9/04 : Inotropic agents, i.e. stim...A61P 9/10 : for treating ischaemic or a...C07D 487/04 : Ortho-condensed systems